Lytix Biopharma: Presentation of third quarter 2023 results, November 9
Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, will release its third quarter 2023 results on Thursday, November 9. The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 2:30 pm CEST.
The presentation and subsequent Q&A session will be held in English and may be viewed live by registering here: https://forms.office.com/e/N0xJzSx0Gg
The presentation will be available at www.lytixbiopharma.com in the Investors section from 08:00 am CET the same day, and a recording of the presentation will after the presentation be made available.
For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager: ole.peter.nordby@lytixbiopharma.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in ‘host defense peptides’ – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors including PBM Capital, a US based, healthcare-focused investment firm.